新着動画一覧

(SPA, BLRX, SURW) CRWENewswire Stocks In Action

BioLineRx Ltd BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C. According to a definitive agreement between the companies, Consolidated Communications Holdings will acquire all the outstanding shares of SureWest Communications - SURW - in a cash and stock transaction valued at $23.00 per share, or a total of approximately $340.9 million, exclusive of debt. Sparton Corp - SPA - reported that it has been awarded an approximately $7.6 million contract by Australia to manufacture the AN/SSQ-62E and AN/SSQ-53F sonobuoys. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

投稿者： karmastock
投稿日時：2012-02-07 04:46:44.0
視聴回数：546回
お気に入り登録：0
カテゴリ：ビジネス全般
タグ： SPA Sparton BLRX SURW Nasdaq:BLRX NYSE:SPA Nasdaq:SURW

(TEAR, BLRX, PLCM) CRWENewswire Stocks In Action

BioLineRx Ltd -BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. On its Fourth quarter fiscal 2011, Polycom Inc - PLCM - posted record consolidated net revenues of $407 million, compared to $340 million in the same period the prior year. and lastly; TearLab Corp - TEAR - reported that after reviewing and accepting labeling submitted to it by the Company, the FDA has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 for the TearLab Osmolarity System. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

投稿者： karmastock
投稿日時：2012-01-25 04:39:01.0
視聴回数：407回
お気に入り登録：0
カテゴリ：ビジネス全般
タグ： PLCM TEAR BLRX Nasdaq:BLRX Nasdaq:TEAR Nasdaq:PLCM

注目のキーワード（タグ）

会社概要｜ソリューション｜お問い合わせ｜スタッフ募集｜利用規約｜プライバシーポリシー